Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

 // News

May 16  

Precision medicine biotechnology company for obesity secures additional institutional capital  from prominent industry leaders to expand the use of its novel phenotyping test and advance  clinical research in weight loss treatment. 

Menlo Park, Calif., May 16, 2024 – Phenomix Sciences (Phenomix), a precision medicine  biotechnology company that brings data intelligence to the treatment of obesity, has secured  $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing  investors, including Health2047. The company has also been awarded a $2.3 million Phase II  Small Business Innovation Research (SBIR) Grant through the National Institutes of Health  (NIH).  

“As leaders in their respective fields of lab testing and patient empowerment, we are excited to  add DexCom and Labcorp as investors as we continue to scale our company. In addition,  Labcorp will provide laboratory testing services,” said Mark Bagnall, CEO of Phenomix. “After  more than a decade of research from our founders, we are thrilled the wider industry is also  seeing the need to treat the obesity epidemic seriously with clinically focused solutions. The  substantial financial backing for Phenomix’s clinically validated precision obesity programs from  prominent companies in the health industry underscores the importance precision medicine is  poised to have on combating obesity.” 

This capital will accelerate the commercialization and adoption of the MyPhenome™ test in the  obesity specialist market and the wider industry. The MyPhenome test equips physicians with  essential tools to develop effective treatment plans including lifestyle and diet intervention as  well as medication and/or procedure recommendations. The MyPhenome test identifies obesity  phenotypes, subtypes of the disease caused by the interaction of a patient’s genes and the  environment. These phenotypes include Hungry Gut, Hungry Brain and Emotional Hunger. As  demonstrated by Phenomix’s co-founders and Mayo Clinic physicians, Andres Acosta, M.D.  Ph.D. and Michael Camilleri, M.D. D.Sc., obesity phenotypes help explain why people exhibit  varying responses to different treatments. 

The funds will also enable the company to develop and launch additional phenotyping tests,  continue to support clinical studies and patent novel insights, and further strategic relationships  with pharmaceutical companies and health care providers.  

The SBIR grant allows the company to perform additional clinical studies demonstrating the  value of obesity precision medicine. The sizable award from the NIH is a testament to the  importance of this work on the future of obesity treatment as well as the esteemed reputation of  Phenomix’s founders and significance of their prior studies. Specifically, the grant will fund a  prospective study of the MyPhenome test and further prove its accuracy in predicting obesity  treatment response.

The company recently launched its new three-in-one MyPhenome obesity phenotyping test,,  including Hungry Gut, Hungry Brain and Emotional Hunger, currently in use by U.S. providers.  For more information, visit  

About Phenomix Sciences 

Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer  obesity globally through the use of our proprietary genetic tests, unique data sets, and  advanced analytics. Mayo Clinic physicians, scientists, and researchers, Andres Acosta, M.D.  Ph.D., and Michael Camilleri, M.D. D.Sc., founded the company after 10 years of rigorous  clinical research focused on uncovering the pathophysiology behind the variability in response  to obesity treatments. Phenomix believes that the key to understanding obesity is its  unprecedented access to clinical and molecular information throughout all stages and  phenotypes of the disease. Phenomix leverages data intelligence for yielding better accuracy in  predicting individual patient response to specific weight loss interventions and reducing the  variability in weight loss results for patients. For more information, please visit 


Success message!
Warning message!
Error message!